Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui Sells 23,508 Shares

Journey Medical Co. (NASDAQ:DERM) CEO Claude Maraoui sold 23,508 shares of Journey Medical stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $5.19, for a total transaction of $122,006.52. Following the transaction, the chief executive officer now owns 2,139,922 shares in the company, valued at approximately $11,106,195.18. This trade represents a 1.09 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website.

Claude Maraoui also recently made the following trade(s):

• On Wednesday, March 5th, Claude Maraoui sold 18,147 shares of Journey Medical stock. The shares were sold at an average price of $5.13, for a total transaction of $93,094.11.

Journey Medical Stock Up 3.2 %

DERM opened at $5.23 on Thursday. The company has a debt-to-equity ratio of 1.81, a quick ratio of 1.03 and a current ratio of 1.38. Journey Medical Co. has a fifty-two week low of $2.85 and a fifty-two week high of $6.89. The firm’s fifty day moving average is $4.54 and its 200 day moving average is $5.07. The stock has a market cap of $109.25 million, a price-to-earnings ratio of -5.56 and a beta of 0.96.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of DERM. Tang Capital Management LLC bought a new stake in Journey Medical in the 4th quarter valued at $6,747,000. Citadel Advisors LLC bought a new stake in Journey Medical in the 4th quarter valued at $174,000. Dimensional Fund Advisors LP bought a new stake in Journey Medical in the 4th quarter valued at $80,000. Kovitz Investment Group Partners LLC increased its holdings in Journey Medical by 112.9% in the 4th quarter. Kovitz Investment Group Partners LLC now owns 24,710 shares of the company’s stock valued at $97,000 after acquiring an additional 13,105 shares during the last quarter. Finally, Geode Capital Management LLC increased its holdings in Journey Medical by 13.5% in the 3rd quarter. Geode Capital Management LLC now owns 108,435 shares of the company’s stock valued at $613,000 after acquiring an additional 12,882 shares during the last quarter. Hedge funds and other institutional investors own 7.25% of the company’s stock.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.